Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer
暂无分享,去创建一个
K. Nakayama | M. Miura | M. Asano | Kazuhiro Sato | Y. Okuda | S. Sakamoto | M. Takeda | Hayato Yokota | Mariko Asano | Sho Sakamoto